Illumina Names Joydeep Goswami Senior Vice President of Corporate Development and Strategic Planning

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (Nasdaq:ILMN) today announced the appointment of Joydeep Goswami as Senior Vice President of Corporate Development and Strategic Planning. Mr. Goswami will be responsible for driving planning, strategic partnerships and acquisitions, and will report to President and Chief Executive Officer, Francis deSouza.

With more than 20 years of global experience, Mr. Goswami has a strong track record of developing strategy and leading new product development, partnerships, licensing, and mergers and acquisitions. Most recently, he served as the President of Thermo Fisher Scientific’s Clinical Next-Generation Sequencing (NGS) and Oncology business unit, where he oversaw efforts that drove the adoption of NGS in clinical oncology, research and reproductive health.

“We are very pleased to welcome Joydeep to Illumina,” said deSouza. “Joydeep’s global experience, entrepreneurial spirit and deep background in research and clinical businesses, will serve Illumina well as we accelerate the adoption of sequencing in existing markets and enable the most impactful, new opportunities for genomics.”

“I am honored to be joining Illumina and look forward to helping harness the power of the genome to shift the paradigm of healthcare and life science research across the globe,” said Goswami.

Mr. Goswami has held senior leadership roles across the pharma/biotech, diagnostics and research tool continuum, previously serving at companies such as Life Technologies and Invitrogen, in addition to Thermo Fisher Scientific. He has led teams across various functions, including sales, marketing, R&D and other support functions. Mr. Goswami served as President, Asia Pacific and Japan while at Thermo Fisher Scientific and created the Stem Cells and Regenerative Medicine Business Unit at Invitrogen. Additionally, he spent five years at McKinsey & Co., where he specialized in strategy for pharmaceutical, medical technology and technology companies.

Mr. Goswami holds his M.S., Ph.D. in Chemical Engineering, an MBA from the Massachusetts Institute of Technology and a Bachelor’s degree in Chemical Engineering from the Indian Institute of Technology, Mumbai.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.

Use of forward-looking statements

This release contains forward-looking statements that involve risks and uncertainties. These forward-looking statements are based on our expectations as of the date of this release and may differ materially from actual future events or results. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are (i) our ability to further develop and commercialize our instruments and consumables, and to deploy new products, services and applications, and expand the markets for our technology platforms; (ii) our ability to manufacture robust instrumentation and consumables; (iii) our ability to successfully identify and integrate acquired technologies, products or businesses; (iv) the future conduct and growth of the business and the markets in which we operate; and (v) challenges inherent in developing, manufacturing, and launching new products and services, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts’ expectations, or to provide interim reports or updates on the progress of the current quarter.

Contacts

Investors:

Jacquie Ross, CFA

858-882-2172

ir@illumina.com

Media:

Eric Endicott

858-882-6822

pr@illumina.com